Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

KORU Medical Systems (KRMD) Income from Continuing Operations (2020 - 2025)

KORU Medical Systems (KRMD) has disclosed Income from Continuing Operations for 11 consecutive years, with 777966.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 50.79% to 777966.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 3691964.0, a 69.16% increase, with the full-year FY2024 number at 6066633.0, up 55.85% from a year prior.
  • Income from Continuing Operations was 777966.0 for Q3 2025 at KORU Medical Systems, down from 189511.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 189511.0 in Q2 2025 to a low of 7466029.0 in Q4 2023.
  • A 5-year average of 1850656.89 and a median of 1368262.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 538.96% in 2021, then soared 80.83% in 2025.
  • KORU Medical Systems' Income from Continuing Operations stood at 1068358.0 in 2021, then tumbled by 85.02% to 1976727.0 in 2022, then crashed by 277.7% to 7466029.0 in 2023, then surged by 79.13% to 1558250.0 in 2024, then skyrocketed by 50.07% to 777966.0 in 2025.
  • Per Business Quant, the three most recent readings for KRMD's Income from Continuing Operations are 777966.0 (Q3 2025), 189511.0 (Q2 2025), and 1166237.0 (Q1 2025).